Immuno-positron emission tomography as a new frontier in imaging hematologic malignancies

doi:10.5306/wjco.v16.i9.108585

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 9

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (846)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-2) series, Tables (1-2) series.

Item

Count

PDF

HTML

Figures (1-2)

Tables (1-2)

Sum=112

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

479

Download

133

Sum=612

Publishing Process of This Article

Item

Count

Browse

Download

Sum=97

Sep 24, 2025 (publication date) through Oct 25, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Clin Oncol. Sep 24, 2025; 16(9): 108585
Published online Sep 24, 2025. doi: 10.5306/wjco.v16.i9.108585

Table 1 Representative positron-emitting radionuclides used in immuno-positron emission tomography for hematologic malignancies

Radionuclide	Emission	Half-life	β⁺ ray emitting rate
Copper-64 (⁶⁴Cu)	β⁺, β^-, EC	12.7 h	19%
Zirconium-89 (⁸⁹Zr)	β⁺, EC	78.4 h	23%
Gallium-68 (⁶⁸Ga)	β⁺, EC	68 min	89%

EC: Electron capture.

Full Size Table

Table 2 Surface antigens targeted in immuno-positron emission tomography for hematologic malignancies

Types of hematologic malignancy	Surface antigens targeted in immuno-PET detection
Non-Hodgkin lymphoma	CD19, CD20, CXCR4
Hodgkin lymphoma	CD30
Multiple myeloma	CD38, CD138, VLA-4, BCMA, SLAMF7, CXCR4
Acute myeloid leukemia	CD33, CXCR4
Acute lymphoblastic leukemia	CXCR4

CXCR4: C-X-C motif chemokine receptor 4; VLA-4: Very late antigen-4; BCMA: B-cell maturation antigen; SLAMF7: Signaling lymphocyte activation molecule F7; Immuno-PET: Immuno-positron emission tomography.

Full Size Table

Citation: Goto H, Takano M, Shiraishi Y, Luanpitpong S. Immuno-positron emission tomography as a new frontier in imaging hematologic malignancies. World J Clin Oncol 2025; 16(9): 108585
URL: https://www.wjgnet.com/2218-4333/full/v16/i9/108585.htm
DOI: https://dx.doi.org/10.5306/wjco.v16.i9.108585